|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
118,790,000 |
Market
Cap: |
42.71(M) |
Last
Volume: |
19,275,386 |
Avg
Vol: |
8,941,637 |
52
Week Range: |
$0.3595 - $0.3595 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1126 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Novavax is a biotechnology company that promotes improved global health through the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its primary influenza vaccine candidate, NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 and NanoFlu include the use of Co.'s proprietary Matrix-M adjuvant.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
6,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$43,042 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
0 |
68,716 |
68,716 |
68,716 |
Total Sell Value |
$0 |
$961,682 |
$961,682 |
$961,682 |
Total People Sold |
0 |
2 |
2 |
2 |
Total Sell Transactions |
0 |
3 |
3 |
3 |
End Date |
2024-06-20 |
2024-03-19 |
2023-09-19 |
2022-09-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Glenn Gregory M |
SVP, Research and Development |
|
2014-03-14 |
4 |
S |
$5.48 |
$158,778 |
D/D |
(29,000) |
4,102 |
|
- |
|
Glenn Gregory M |
SVP, Research and Development |
|
2014-03-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
33,102 |
|
- |
|
Glenn Gregory M |
SVP, Research and Development |
|
2014-01-31 |
4 |
B |
$2.29 |
$9,394 |
D/D |
4,102 |
31,000 |
2.74 |
- |
|
Wilson Russell P |
SVP, Business Development |
|
2014-01-31 |
4 |
B |
$2.29 |
$11,221 |
D/D |
4,900 |
54,900 |
2.74 |
- |
|
Hahn Timothy Jon |
SVP, Manufacturing & PD |
|
2014-01-31 |
4 |
B |
$2.29 |
$21,563 |
D/D |
9,416 |
80,416 |
2.74 |
- |
|
Phillips Barclay A |
SVP, Chief Financial Officer |
|
2014-01-31 |
4 |
B |
$2.29 |
$22,598 |
D/D |
9,868 |
9,868 |
2.74 |
- |
|
Erck Stanley C |
President and CEO |
|
2014-01-31 |
4 |
B |
$2.29 |
$27,178 |
D/D |
11,868 |
74,868 |
2.81 |
- |
|
Phillips Barclay A |
SVP, Chief Financial Officer |
|
2013-06-12 |
4/A |
B |
$0.00 |
$0 |
D/D |
0 |
0 |
2.66 |
- |
|
Phillips Barclay A |
Director |
|
2013-06-12 |
4 |
B |
$1.90 |
$95,000 |
D/D |
50,000 |
200,000 |
2.39 |
- |
|
Douglas Richard |
Director |
|
2013-06-12 |
4 |
B |
$1.90 |
$95,000 |
D/D |
50,000 |
200,000 |
2.39 |
- |
|
Hahn Timothy Jon |
SVP, Manufacturing & PD |
|
2013-06-10 |
4 |
B |
$1.88 |
$39,480 |
D/D |
21,000 |
71,000 |
2.74 |
- |
|
Glenn Gregory M |
Chief Scientific Officer |
|
2013-06-07 |
4 |
B |
$1.83 |
$1,830 |
D/D |
1,000 |
31,000 |
2.66 |
- |
|
Glenn Gregory M |
Chief Scientific Officer |
|
2013-06-06 |
4 |
B |
$2.01 |
$2,010 |
D/D |
1,000 |
30,000 |
2.66 |
- |
|
Young James F |
Director |
|
2013-06-06 |
4 |
B |
$1.91 |
$191,000 |
D/D |
100,000 |
400,000 |
2.39 |
- |
|
Evans Gray C |
Director |
|
2013-04-24 |
4 |
S |
$2.44 |
$193,540 |
D/D |
(79,000) |
702,558 |
|
- |
|
Young James F |
Director |
|
2013-03-11 |
4 |
B |
$2.03 |
$203,000 |
D/D |
100,000 |
300,000 |
2.39 |
- |
|
Hahn Timothy Jon |
SVP, Manufacturing & PD |
|
2012-05-14 |
4 |
B |
$1.33 |
$39,900 |
D/D |
30,000 |
50,000 |
2.74 |
- |
|
Glenn Gregory M |
Chief Scientific Officer |
|
2012-05-10 |
4 |
B |
$1.35 |
$33,750 |
D/D |
25,000 |
29,000 |
2.74 |
- |
|
Douglas Richard |
Director |
|
2012-04-10 |
4 |
B |
$1.21 |
$60,500 |
D/D |
50,000 |
200,000 |
2.39 |
- |
|
Glenn Gregory M |
Chief Scientific Officer |
|
2011-12-05 |
4 |
B |
$1.50 |
$3,000 |
D/D |
2,000 |
418,000 |
2.66 |
- |
|
Young James F |
Director |
|
2011-12-01 |
4 |
B |
$1.46 |
$292,000 |
D/D |
200,000 |
440,000 |
2.39 |
- |
|
Wilson Russell P |
SVP, Business DevelopmentOffic |
|
2011-12-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,000 |
|
- |
|
Glenn Gregory M |
Chief Scientific Officer |
|
2011-11-29 |
4 |
B |
$1.26 |
$2,520 |
D/D |
2,000 |
416,000 |
2.66 |
- |
|
Hahn Timothy Jon |
SVP, Manufacturing & PDOfficer |
|
2011-09-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,000 |
|
- |
|
Evans Gray C |
Director |
|
2011-08-23 |
4/A |
S |
$1.22 |
$581,423 |
D/D |
(476,576) |
773,878 |
|
- |
|
151 Records found
|
|
Page 2 of 7 |
|
|